Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082564 | 0.76 | ALDH1A1 (0.41) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL23873708 | 0.72 | L3MBTL1 (0.38) | L3MBTL1PTPN1ALDH1A1PRKCA | |
| SCHEMBL3077632 | 0.71 | PTPN1 (0.47) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL26502837 | 0.71 | PTGES (0.34) | — | |
| SCHEMBL15564118 | 0.71 | KMT2A (0.40) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL2310858 | 0.71 | ALDH1A1 (0.41) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL20786806 | 0.69 | PTPN1 (0.46) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL7059040 | 0.68 | ALDH1A1 (0.39) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL9730908 | 0.68 | — | — | |
| SCHEMBL12041925 | 0.67 | ALDH1A1 (0.45) | L3MBTL1PTPN1ALDH1A1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182471-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-06-06 | — | — | US | disclosed |
| US-11912704-B2 | Methods and compositions for substituted arylcycloheptane analogs | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912704-B2 | Methods and compositions for substituted arylcycloheptane analogs | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912704-B2 | Methods and compositions for substituted arylcycloheptane analogs | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210300928-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210300928-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020033567-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033567-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| WO-2010070593-A2 | MALONATE ESTERS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070593-A2 | MALONATE ESTERS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2007127309-A2 | PROCESSES FOR THE SYNTHESIS OF 3-ISOBUTYLGLUTARIC ACID | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259917-A1 | Processes for the synthesis of 3-isobutylglutaric acid | TEVA PHARMACEUTICALS USA, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259917-A1 | Processes for the synthesis of 3-isobutylglutaric acid | TEVA PHARMACEUTICALS USA, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300928-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | AHR, HCCS, HMBS | L3MBTL1 3902/4885PTPN1 2317/4885ALDH1A1 529/4885 |
| US-20240182471-A1 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | AHR, HCCS, HMBS | L3MBTL1 3902/4885PTPN1 2317/4885ALDH1A1 529/4885 |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | L3MBTL1 2575/4885PTPN1 3818/4885ALDH1A1 2507/4885 |
| US-20070259917-A1 | Processes for the synthesis of 3-isobutylglutaric acid | OGDH, GLUL, PGD | L3MBTL1 2890/4885PTPN1 4687/4885ALDH1A1 838/4885 |
| US-11912704-B2 | Methods and compositions for substituted arylcycloheptane analogs | AHR, HCCS, HMBS | L3MBTL1 3902/4885PTPN1 2317/4885ALDH1A1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.